Objective. IL-35 is the most recently identified member of the IL-12 family. It consists of EBV-induced gene 3 (EBI3) and IL-12a chain p35. We investigated whether IL-35 enhances the in vitro immunosuppressive function of peripheral blood isolated from patients with RA.
Introduction
Treg are a unique subset of CD4 + T cells that are essential for regulating autoimmune disease. Naturally occurring Treg (nTreg) are a small population of thymus-derived CD4 + T cells that are characterized by the constitutive expression of the IL-2Ra chain (CD25) without antigen responses [1] . Recently the lineage-specific transcription factor forkhead box P3 (FoxP3) was determined to be a key hallmark of nTreg, functioning as the master regulatory gene during their development and function [24] . Although nTreg can suppress the responses of effector T cells [5, 6] , their underlying mechanism of action remains unclear.
Recently a novel member of the IL-12 family of cytokines, IL-35, was found to be involved in the enhanced function of Treg in vitro and in vivo [79] . IL-35 is a heterodimeric cytokine composed of the EBV-induced gene 3 (EBI3) and the p35 subunit of IL-12. It is constitutively expressed by mouse Treg, but not by CD4 + CD25 À conventional responder T cells (Tres) [8, 9] . Maximal expression and secretion of IL-35 requires cellcell contact between Treg and Tres. The loss of IL-35 expression reduces the in vivo suppressive capacity of Treg.
In addition, recombinant mouse IL-35 enhanced the proliferation of Treg and suppressed the proliferation of Tres when cultured with soluble anti-CD3 antibody and antigen presenting cells (APCs) in vitro [7] . The IL-35 receptor is IL-12Rb2 and gp130, and its signalling cascade is known [10] . Therefore IL-35 plays a crucial role in Treg-mediated immune suppression.
To explore the possible involvement of IL-35 in autoimmune disease, Niedbala et al. [7] showed that recombinant IL-35 effectively attenuated CIA, a mouse model of RA, via mechanisms involving the suppression of T cell proliferation and Th17 cell differentiation. Kochetkova et al. [11] also reported that recombinant IL-35 treatment inhibited the progression of murine CIA and that Treg stimulated with IL-35 produced IL-10 in vitro. These data suggest that enhanced production of IL-10 might play a role in the effects of IL-35 on CIA. This same study also reported that IL-35 suppressed T cell proliferation and Th17 differentiation [11] . In an additional study, Valencia et al. [12] reported that Treg isolated from patients with active RA expressed reduced levels of FoxP3 and poorly suppressed effector T cells; however, their suppressive function was restored after treatment with an anti-TNF antibody in vitro [12] . Taken together, these studies suggest that Treg from patients with RA exhibit reduced ability to suppress the production of two principal pro-inflammatory cytokines by effector T cells [13] .
However, little is known regarding the definitive mechanisms of IL-35 in autoimmune disease. Therefore we investigated the immunoregulatory role of IL-35 in patients with RA.
Patients and methods

Patients and clinical data assessments
Peripheral blood was obtained from 17 patients with active RA, 11 with inactive RA (Table 1 ) and 20 healthy controls. All RA patients met the 1987 ACR criteria [14] . The following clinical parameters were assessed: RF, MMP-3, ACPA and the 28-joint DAS based on CRP (DAS28-CRP). RA disease activity can be interpreted as low (DAS28-CRP <2.7), moderate (DAS28-CRP 2.7À4.1) or high (DAS28-CRP >4.1) [15] . Moderate and high disease activity patients were defined as having active RA, whereas those with low disease activity had inactive RA. This study was approved by the ethics committee of Juntendo University and was performed in accordance with the principles outlined in the Declaration of Helsinki. Signed informed consent was obtained from all patients and healthy controls prior to starting the study.
Antibodies and reagents
Mouse monoclonal FLAG (M2 antibody) and fluorescein isothiocyanateconjugated M2 antibodies were purchased from Sigma-Aldrich (St Louis, MO, USA). Rabbit polyclonal antibodies against b-actin (H-196) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phycoerythrincyanin 5labelled anti-human CD4 (RPA-T4) antibodies were purchased from eBioscience (San Diego, CA, USA). PE-conjugated anti-human CD25 (2A3) and Alexa Fluor 647labelled anti-human CD127 (A7R34) antibodies were obtained from BD Pharmingen (San Diego, CA, USA). 5,6-carboxy fluorescein diacetate succinimidyl ester (CFSE) was purchased from Invitrogen (Eugene, OR, USA). Anti-biotin MACSiBead particles preloaded with biotinylated CD2 (LT2), CD3 (OKT3) and CD28 (15E8) antibodies (Treg Suppression Inspector) were obtained from Miltenyi Biotec (Bergish Gladbach, Germany). All DNA oligonucleotides (oligos) were obtained from Hokkaido System Science (Sapporo, Hokkaido, Japan).
Construction of IL-35 expression vector
IL-35, FLAG-tagged at the C-terminus, was constructed using the p3 Â FLAG-CMV-13 vector (Sigma-Aldrich). A pre-protrypsin leader sequence (PPTLS) was added to the N-terminus of FLAG-tagged IL-35 to trigger spontaneous secretion. The covalent linkage of human EBI3 and IL-12a/p35 was mediated by self-cleaving 2A peptide (VKQTLNFDLLKLAGDVESNPGP) [16] or the linker peptide (3 Â GGGGS) [7, 8] . The IL-35 expression constructs were created as described below. Annealed double-stranded oligos encoding a linker peptide were subcloned into the p3 Â FLAG-CMV-13 vector at the EcoRI and ClaI restriction enzyme sites. Human full-length DNAs encoding 0 . HindIII and NotI restriction sites were introduced into EBI3 and a ClaI site was introduced into IL12a/p35. The PCR fragments containing the EBI3 and IL12a /p35 sequences were then serially subcloned into the p3 Â FLAG-CMV-13 vector to form a pPPTLS EBI3linkerIL-12a/p353 Â FLAG expression construct. All restriction enzymes were purchased from New England Biolabs (Ipswich, MA, USA). In-frame expression was confirmed by sequencing.
Preparation of human IL-35
The FLAG-tagged human IL-35 expression construct was transfected into HEK293 cells using the calcium phosphate method. A p3XFLAGCMV-13 vector containing only a portion of the linker peptide was also used as a control. The culture medium was switched to X-VIVO15 (Cambrex Bio Science, Walkersville, MD, USA) 24 h after transfection; IL-35 supernatants were then harvested after a 3-day incubation.
Immunoblotting
Immunoblotting was performed according to standard methodologies. Briefly, cells were lysed gently in icecold buffer containing 1% Nonidet P-40, 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and 30 mM NaF supplemented with protease inhibitors (Protease Inhibitor Cocktail Set V; EMD Chemicals, Darmstadt, Germany). Lysates were clarified by centrifugation at 10 000 g at 4 C. Extracts were separated by SDS-PAGE, transferred to nitrocellulose membranes, probed with anti-FLAG M2 antibodies and then incubated with a secondary antibody conjugated to horseradish peroxidase (Amersham Biosciences, Arlington Heights, IL, USA). Blots were developed using an enhanced chemiluminescent substrate (Super Signal West Pico; Pierce, Rockford, IL, USA) and visualized using a LumiVision analyser (Taitec, Tokyo, Japan).
Isolation of T cell subsets
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors and patients with RA using Ficoll-Hypaque density gradient centrifugation. Monocytes were depleted by adherence to the plastic surfaces of the culture dishes. Next, 1 Â 10 7 lymphocytes were resuspended in 600 ml of PBS containing 3% fetal calf serum and labelled with 5 ml of phycoerythrincyanin 5 conjugated anti-human CD4, 5 ml of phycoerythrin conjugated anti-human CD25 and 5 ml of Alexa Fluor 647 antihuman CD127 antibodies. After incubation for 20 min at 4 C, fluorochrome-labelled T cells were separated into CD4 + CD127 0 -aaacctccccgtggccactcc-3 0 and reverse 5 0 -gaagc attcagatagctcatcact-3 0 ) and b-actin (forward 5 0 -caaggcca accgcgagaagatgac-3 0 and reverse 5 0 -aggaaggaaggctgga agagtgc-3 0 ) and 1 mg of cDNA. The cycling conditions were denaturation at 95 C for 10 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min for annealing and extension. The expression of EBI3 and IL-12a/p35 was measured on an ABI Prism 7500 Sequence Detection System (Applied BioSystems). PCR products were separated on a 2% agarose gel and stained with ethidium bromide. The levels of EBI3 and IL-12a/p35 in each sample were normalized to b-actin.
Measuring serum IL-35 and IL-10
Human IL-35 concentrations were quantified using an ELISA kit (LEGEND MAX Human IL-35 Heterodimer ELISA Kit with pre-coated plates; BioLegend, San Diego, CA, USA) following the manufacturer's instructions. The concentrations of human IL-10 (R&D Systems, Minneapolis, MN, USA) were quantified by ELISA following the manufacturer's instructions.
In vitro suppression assay A CFSE-based assay for measuring the regulatory function of CD4 + CD127 À CD25 + Treg was performed as described previously [17] . CD4 + CD127 + CD25 À Tres (1 Â 10 6 /ml) were suspended in PBS/0.1% BSA and incubated with 10 mM CFSE for 10 min at 37 C. Ice-cold X-VIVO15 was then added to the cell suspensions, which were incubated on ice for 5 min to quench the staining. CFSE-labelled Tres were washed three times and resuspended in X-VIVO15. Before plating the cells, 10 ml of AB serum (TaKaRa BIO, Shiga, Japan) was added to 96-well round-bottom plates (Iwaki, Tokyo, Japan). CFSE 
Statistical analysis
All data were expressed as mean (S.D.). Statistical analyses were performed using the MannWhitney U-test, SteelDwass method and Pearson's correlation coefficient. Statistical significance was defined as P < 0.05.
Results
Construction of a human IL-35 expression vector
We devised a construct encoding human IL-35 by covalently linking intact EBI3 with IL-12a/p35-FLAG protein, as described previously for mouse 8] . A secretory signal sequence (PPTLS) was added to the N-terminus of EBI3 to promote spontaneous secretion and EBI3 was linked to IL-12a/p35 with two different types of linker: native IL-35 (self-cleaving 2A peptide) and single chain IL-35 (3 Â GGGGS linker peptide) (Fig. 1A) . Harvested supernatants from HEK293 cells transfected with these expression vectors showed a high yield and enriched soluble production of human IL-35 (Fig. 1B) .
Expression of IL-35 in Treg isolated from RA patients
Next we determined the Treg:Tres ratio and mRNA expression level of p35 and EBI3, the two components of IL-35, in peripheral blood isolated from patients with active RA. However, there were no significant differences in the expression of IL-35 in Treg cells from patients with active RA vs healthy donors ( Fig. 2A) and active RA vs inactive RA (data not shown). The ratio of CD4 + CD127 À CD25 + Treg was decreased in patients with active RA compared with that in RA patients with stable disease whose symptoms had been suppressed by treatment (Fig. 2B) .
Expression of serum IL-35 in RA patients and correlations with clinical data
We examined serum IL-35 levels in patients with RA and found the levels were significantly decreased in these patients (*P < 0.05, **P < 0.01; Fig. 3A) . Moreover, serum IL-35 levels were significantly higher in patients with inactive vs active RA (*P < 0.05, **P < 0.01).
FIG. 1 Construction and production of recombinant human IL-35
(A) Schematic diagram of the IL-35 construct. IL-35, tagged with 3 Â FLAG at the C-terminus, was used to covalently link EBV-induced gene 3 (EBI3) and IL-12a chain p35 (IL-12a/p35) by alternately employing two linker peptides: a selfcleaving 2A peptide (VKQTLNFDLLKLAGDVESNPGP) and a linker peptide (3 Â GGGGS). Pre-protrypsin leader sequence (PPTLS) was added to the N-terminus of IL-35 to allow spontaneous secretion. (B) Western blotting of recombinant IL-35. 293EBNA cells were transfected with two types of IL-35-encoding expression vector or p3XFLAG-CMV13 empty vector. Twenty-four hours after transfection, the culture medium was switched from DMEM containing 10% fetal calf serum to serum-free X-VIVO15 medium. Supernatants were harvested after 3 days of culture and then analysed by western blotting using anti-FLAG antibodies.
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Next we investigated the relationship between serum IL-35 levels in patients with RA and clinical parameters (DAS28-CRP, RF, MMP-3 and ACPA) and demonstrated a significant inverse correlation with DAS28-CRP ( Fig. 3B ; P < 0.01, R = À0.794). In contrast, RF, MMP-3 and ACPA were not correlated with IL-35 (data not shown). It was dispersion data on CRP and ESR (data not shown) in patients with RA, therefore CRP and ESR were not correlated with IL-35. Moreover, serum IL-10 levels were not correlated with serum IL-35 levels.
Effect of IL-35 on the regulatory potential of Treg
To examine the suppressive effect of human IL-35 on the regulatory capacity of nTreg, FACS-sorted Treg and autologous Tres from patients with RA were co-cultured with human IL-35 in vitro. Isolated Tres were labelled with CFSE to allow Tres and Treg to be easily distinguished; non-labelled CD25 + Treg could be excluded from the analysis because they did not emit the CFSE signal. The CFSE division profile of Tres activated by anti-CD2-, anti-CD3-and anti-CD28-coated microbeads was then assessed over a 5 day incubation. There were up to four discrete division cycles of control cells, which was clearly reduced to two division cycles by co-culture of activated Treg with Tres at a ratio of 1:3 (Fig. 4A) . Culture supernatants containing human full-length IL-35, not the linker peptide without EBI3 and IL-12a/p35, significantly enhanced the suppressive capacity of Treg with an increase in non-divided Tres (Fig. 4B ). In contrast, there were no differences in the population of non-divided Tres that were co-cultured with Treg between native 2A and linker IL-35 supernatants (data not shown). IL-35 supernatants had no effect on the proliferation of activated Tres in response to anti-CD3/CD28 in the absence of Treg (data not shown). Therefore activated Tres in patients with RA were more differentiated to Th1 or Th17 and up-regulated IFN-g and IL-17 production. In cytokine analysis, IL-35 treatment significantly suppressed the levels   FIG. 3 Expression of IL-35 in the serum of RA patients and correlations with clinical parameters (A) Serum IL-35 levels were measured using ELISA in 28 patients with RA and 20 normal controls. Serum IL-35 levels were significantly decreased (*P < 0.05, **P < 0.01) in RA patients. (B) Serum IL-35 levels correlated with the 28-joint DAS based on CRP (DAS28-CRP) in patients with RA (P < 0.01, R = 0.794).
www.rheumatology.oxfordjournals.org of IL-17 (Fig. 4C ) and IFN-g (Fig. 4D ), but not IL-10 (data not shown). These data reveal the immunosuppressive properties of IL-35, whereby it enhances Treg activity in patients with RA (see supplementary Fig. S1A and S1B, available at Rheumatology Online).
Discussion
In the current study we demonstrated a potential role for IL-35 as a negative regulator of peripheral immune responses in patients with RA. First, we assessed the levels of IL-35 in the serum of patients with RA and SLE and found that IL-35 production was significantly reduced in RA compared with healthy controls and patients with SLE. Moreover, there was preferential expression of EBI3 in natural Treg isolated from the peripheral blood of RA patients. We constructed a novel expression vector encoding FLAG-tagged EBI3 linked to IL-12a/p35 and identified the selective binding of human IL-35 to activated Treg (see supplementary Fig. S1A and S1B, Our study also suggests that the antigens that activate Treg via TCR and CD28 signalling are highly sensitive to IL-35 and enhance Treg-mediated suppression of activated helper T cells in an autocrine manner. Consistent with this, IL-35-deficient Treg failed to control the homeostatic expansion of Tres and were less able to exert effects in established colitis compared with wild-type Treg [26] . Interestingly, IL-35-deficient Treg isolated from either Ebi3 À/À or Il12a À/À mice failed to enhance suppression [27] . Under conditions such as chronic infection or inflammation, we suggest that IL-35 enhances Treg function as part of the peripheral immune response to prevent the onset of excessive autoimmune responses in Treg.
Although many previous studies have implicated Treg in the pathogenesis of human autoimmune diseases, none has examined the role of IL-35 specifically. This is the first study to suggest the possible involvement of IL-35 in the pathophysiology of RA (see supplementary Fig. S2 , available at Rheumatology Online). Although current treatment strategies for RA, including anti-TNF therapy, aim mainly to control inflammation, our data suggest that IL-35 and Treg might have multiple therapeutic targets.
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